Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 271

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 271
---
 LIABILITY (Cont.) |

On March 11, 2023, following the 2021
Note conversion, the warrants became exercisable into 132,577 preferred D-2 shares at an exercise price of $12.16 per warrant. The warrants
are exercisable until December 31, 2023.

The number of the warrants and exercise
price were adjusted retroactively to reflect the Split, see Note 1c.

The Company estimates the fair value
of the warrant using PWERM. For the years ended December 31, 2023, the Company recorded an income of $5 as change in fair value of the
warrant. On January 1, 2024, the warrants expired as they were not exercised and the Company recorded an income at the amount of $402.

| NOTE 8:- | TAXES ON INCOME |

| a. | Tax rates applicable to the Company: |

| b. | Net operating loss and capital carry forward: |

As of December 31, 2024, the Company
had net operating loss carry forwards and capital loss carry forward for Israeli income tax purposes of approximately $38,940 and $117,
respectively. Net operating loss carry forwards in Israel may be carried forward indefinitely and offset against future taxable
income.

| d. | Deferred income taxes: |

Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the
amounts used for income tax purposes.

<div align='center'>F-20</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 8:- | TAXES ON INCOME (Cont.) |

Significant components of the Company’s
deferred tax assets are as follows:

| Deferred tax assets:                                                           |     | December 31, 
 2024         |        |   |     | 2023 |        |   |
|:-------------------------------------------------------------------------------|:----|:-------------|-------:|:--|:----|:-----|-------:|:--|
| Net operating loss carry forward                                               |     | $            | 38,940 |   |     | $    | 40,064 |   |
| Deferred tax asset on capital loss carrying forward before valuation allowance |     |              |  8,956 |   |     |      |  9,214 |   |